1,293 reports of this reaction
3.4% of all DABRAFENIB reports
#6 most reported adverse reaction
CHILLS is the #6 most commonly reported adverse reaction for DABRAFENIB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,293 FDA adverse event reports linking DABRAFENIB to CHILLS. This represents approximately 3.4% of all 37,967 adverse event reports for this drug.
Patients taking DABRAFENIB who experience chills should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHILLS is moderately reported among DABRAFENIB users, representing a notable but not dominant share of adverse events.
In addition to chills, the following adverse reactions have been reported for DABRAFENIB:
The following drugs have also been linked to chills in FDA adverse event reports:
CHILLS has been reported as an adverse event in 1,293 FDA reports for DABRAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHILLS accounts for approximately 3.4% of all adverse event reports for DABRAFENIB, making it a notable side effect.
If you experience chills while taking DABRAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.